ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia

Recent evidence suggests that - in addition to 17p deletion - TP53 mutation is an independent prognostic factor in chronic lymphocytic leukemia (CLL). Data from retrospective analyses and prospective clinical trials show that ∼5% of untreated CLL patients with treatment indication have a TP53 mutati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Pospíšilová, Šárka (VerfasserIn) , Zenz, Thorsten (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 6 March 2012
In: Leukemia
Year: 2012, Jahrgang: 26, Heft: 7, Pages: 1458-1461
ISSN:1476-5551
DOI:10.1038/leu.2012.25
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1038/leu.2012.25
Verlag, Volltext: https://www.nature.com/articles/leu201225
Volltext
Verfasserangaben:S. Pospisilova, D. Gonzalez, J. Malcikova, M. Trbusek, D. Rossi, A. P. Kater, F. Cymbalista, B. Eichhorst, M. Hallek, H. Döhner, P. Hillmen, M. van Oers, J. Gribben, P. Ghia, E. Montserrat, S. Stilgenbauer and T. Zenz

MARC

LEADER 00000caa a2200000 c 4500
001 1580644155
003 DE-627
005 20220815001312.0
007 cr uuu---uuuuu
008 180904s2012 xx |||||o 00| ||eng c
024 7 |a 10.1038/leu.2012.25  |2 doi 
035 |a (DE-627)1580644155 
035 |a (DE-576)510644155 
035 |a (DE-599)BSZ510644155 
035 |a (OCoLC)1341017862 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Pospíšilová, Šárka  |e VerfasserIn  |0 (DE-588)1166155498  |0 (DE-627)1030039895  |0 (DE-576)510644279  |4 aut 
245 1 0 |a ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia  |c S. Pospisilova, D. Gonzalez, J. Malcikova, M. Trbusek, D. Rossi, A. P. Kater, F. Cymbalista, B. Eichhorst, M. Hallek, H. Döhner, P. Hillmen, M. van Oers, J. Gribben, P. Ghia, E. Montserrat, S. Stilgenbauer and T. Zenz 
264 1 |c 6 March 2012 
300 |a 4 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 04.09.2018 
520 |a Recent evidence suggests that - in addition to 17p deletion - TP53 mutation is an independent prognostic factor in chronic lymphocytic leukemia (CLL). Data from retrospective analyses and prospective clinical trials show that ∼5% of untreated CLL patients with treatment indication have a TP53 mutation in the absence of 17p deletion. These patients have a poor response and reduced progression-free survival and overall survival with standard treatment approaches. These data suggest that TP53 mutation testing warrants integration into current diagnostic work up of patients with CLL. There are a number of assays to detect TP53 mutations, which have respective advantages and shortcomings. Direct Sanger sequencing of exons 4-9 can be recommended as a suitable test to identify TP53 mutations for centers with limited experience with alternative screening methods. Recommendations are provided on standard operating procedures, quality control, reporting and interpretation. Patients with treatment indications should be investigated for TP53 mutations in addition to the work-up recommended by the International workshop on CLL guidelines. Patients with TP53 mutation may be considered for allogeneic stem cell transplantation in first remission. Alemtuzumab-based regimens can yield a substantial proportion of complete responses, although of short duration. Ideally, patients should be treated within clinical trials exploring new therapeutic agents. 
700 1 |a Zenz, Thorsten  |d 1970-  |e VerfasserIn  |0 (DE-588)114963738  |0 (DE-627)577184202  |0 (DE-576)180278266  |4 aut 
773 0 8 |i Enthalten in  |t Leukemia  |d London : Springer Nature, 1997  |g 26(2012), 7, Seite 1458-1461  |h Online-Ressource  |w (DE-627)32046699X  |w (DE-600)2008023-2  |w (DE-576)094139733  |x 1476-5551  |7 nnas  |a ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia 
773 1 8 |g volume:26  |g year:2012  |g number:7  |g pages:1458-1461  |g extent:4  |a ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia 
856 4 0 |u http://dx.doi.org/10.1038/leu.2012.25  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://www.nature.com/articles/leu201225  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180904 
993 |a Article 
994 |a 2012 
998 |g 114963738  |a Zenz, Thorsten  |m 114963738:Zenz, Thorsten  |p 17  |y j 
999 |a KXP-PPN1580644155  |e 3024674888 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Gesehen am 04.09.2018"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1580644155","language":["eng"],"person":[{"roleDisplay":"VerfasserIn","display":"Pospíšilová, Šárka","role":"aut","family":"Pospíšilová","given":"Šárka"},{"role":"aut","display":"Zenz, Thorsten","roleDisplay":"VerfasserIn","given":"Thorsten","family":"Zenz"}],"title":[{"title":"ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia","title_sort":"ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia"}],"physDesc":[{"extent":"4 S."}],"relHost":[{"title":[{"title":"Leukemia","subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title_sort":"Leukemia"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 15.03.04"],"disp":"ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemiaLeukemia","recId":"32046699X","language":["eng"],"pubHistory":["Nachgewiesen 11.1997 -"],"part":{"pages":"1458-1461","issue":"7","year":"2012","extent":"4","text":"26(2012), 7, Seite 1458-1461","volume":"26"},"origin":[{"dateIssuedDisp":"1997-","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","dateIssuedKey":"1997","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke"}],"id":{"zdb":["2008023-2"],"eki":["32046699X"],"issn":["1476-5551"]},"physDesc":[{"extent":"Online-Ressource"}]}],"name":{"displayForm":["S. Pospisilova, D. Gonzalez, J. Malcikova, M. Trbusek, D. Rossi, A. P. Kater, F. Cymbalista, B. Eichhorst, M. Hallek, H. Döhner, P. Hillmen, M. van Oers, J. Gribben, P. Ghia, E. Montserrat, S. Stilgenbauer and T. Zenz"]},"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"6 March 2012"}],"id":{"eki":["1580644155"],"doi":["10.1038/leu.2012.25"]}} 
SRT |a POSPISILOVERICRECOMM6201